Home » State Calls for More Transparency in Clinical Trial Relationships
State Calls for More Transparency in Clinical Trial Relationships
Clinical trial investigators in New
Jersey could be subject to greater transparency requirements if the state acts on recommendations made by the Attorney General’s Division of Consumer Affairs (DCA). Many of the DCA’s
recommendations included in a report released
recently attempt to limit or eliminate financial conflicts of interest between physicians and the drug and device industries, and several of them address
research activities, putting much of the burden of disclosure on physicians.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May